Decoding Treatment Response and Prognosis in Unresectable Locally Advanced Non–Small Cell Lung Cancer by Integrating Spatiotemporal Heterogeneity From 18F-FDG Positron Emission Tomography-Computed Tomography: A Multicenter Study
This study establishes a noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT that reliably predicts treatment response and prognostic outcomes in unresectable LA-NSCLC and offers valuable insights for personalized clinical decision making and supports precision oncology.
Abstract
Purpose Treatment response in unresectable locally advanced non–small cell lung cancer (LA-NSCLC) is highly variable due to marked intratumoral heterogeneity, while existing predictive biomarkers lack accuracy. We aimed to develop and validate a pretreatment 18F-FDG positron emission tomography (PET)-computed tomography (CT)–derived spatiotemporal heterogeneity model to predict treatment response and prognosis in unresectable LA-NSCLC, and to explore its biological underpinnings. Materials and Methods In a multicenter cohort of 434 patients with unresectable LA-NSCLC (training: n = 215; internal validation: n = 93; external validation: n = 126), treatment response was classified as responsive or nonresponsive based on initial assessment. Four distinct habitats (PEThigh-CThigh, PETlow-CTlow, PETlow-CThigh, and PEThigh-CTlow) were generated via the Otsu algorithm. Temporal heterogeneity was quantified using metabolic hotspot displacement (normalized distance from the hotspot to the tumor centroid and normalized distance from the hotspot to the tumor periphery) and integrated with spatial radiomics to build a multidimensional spatiotemporal model. Model performance was evaluated against conventional metrics, with interpretability enhanced via nomogram and SHapley Additive exPlanations analysis. Survival outcomes were assessed using Kaplan-Meier curves, and public transcriptomic data were analyzed to characterize underlying pathways. Results The spatiotemporal model accurately predicted treatment response with AUCs of 0.822 (training), 0.821 (internal validation), and 0.810 (external validation), significantly outperforming conventional whole-tumor PET-CT models. It maintained robust generalizability across treatment subgroups and effectively stratified patients by progression-free survival and overall survival (P < .01). PEThigh-CThigh habitat volume fraction correlated with treatment resistance, whereas PETlow-CTlow habitat correlated with better response. Exploratory pathway analysis highlighted key pathways involving drug metabolism, glycolytic reprogramming, and immune microenvironment remodeling. Conclusion This study establishes a noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT that reliably predicts treatment response and prognostic outcomes in unresectable LA-NSCLC. It offers valuable insights for personalized clinical decision making and supports precision oncology.
Background Pathological complete response (pCR) and major pathological response (MPR) are early measures of treatment efficacy with prognostic relevance in patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy. Individual biomarkers such as programmed cell death-ligand 1 (PD-L1) and...
Ao Li, Zi-Hao Mao, Hai-Long Wang et al.· Translational Lung Cancer Re...· 0 citations
Pathological complete response (pCR) after neoadjuvant therapy is achieved in only about 20%–40% of patients with locally advanced esophageal cancer (LAEC), yet it is the strongest determinant of long-term survival.
18
F-fluorodeoxyglucose (
18
F-FDG) positron emission tomography/computed tomography (PET/CT)...
Jie Li, S. Suppiah, Lingeswaran Kasilingam et al.· Frontiers in Medical Enginee...· 0 citations
It is suggested that uPAR PET captures invasion-related tumor biology that is not fully reflected by glucose metabolism imaging that is not fully reflected by glucose metabolism imaging in non-small cell lung cancer.
P. Soldath, M. Clausen, Annika Loft et al.· Journal of Nuclear Medicine· 0 citations
BACKGROUND
Quantitative fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers are associated with prognosis following stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (ES-NSCLC); however, their relationship with patterns of failure remains poorly defined. We evaluated the...
D. Jayamanne, J. Chan, Riche Mohan et al.· Clinical Lung Cancer· 0 citations
Computed tomography biomarkers after neoadjuvant immunotherapy are examined, focusing on conventional and dual-energy CT, radiomics, delta-radiomics, and deep-learning models.
Yu Li, Lan-Cao Wen· Frontiers in Medicine· 0 citations
IntroductionAccurate identification of epidermal growth factor receptor mutation status is essential for treatment planning in locally advanced non-small cell lung cancer, but tissue testing may be limited by specimen availability and sampling. We developed and externally validated a fluorine-18 fluorodeoxyglucose posi...
Hao-Ran Lian, Hai-Feng Deng, Jing-Song Zheng et al.· Technology in Cancer Researc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.